British Columbia

General contact information for trials in British Columbia:

Current trials:

MK-7902-005/E7080-G000-224/LEAP-005

Recruiting location in British Columbia:

  • Abbotsford – BC Cancer Abbotsford (study coordinator 604-851-4716 Ext 44741)

ID Number: NCT03797326

Links:

Description:This study is looking at the safety and effectiveness of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/Mk-7902).

Group A: Pembrolizumab and lenvatinib

Intervention: Pembrolizumab is an immunotherapy drug that will help immune system cells to attack and get rid of cancer cells. Lenvatinib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.

Can I consider participating?

  • YES:  patients who have a metastatic and/or unresectable solid tumor that is uncurable, has received 2 prior lines of therapy
  • NO: patients who have gastrointestinal condition, active infection or autoimmune disease